Merck reported solid Q4 and full-year 2011 results, with strong performances from key products like JANUVIA and GARDASIL. Despite upcoming challenges such as the SINGULAIR patent expiry, management expressed confidence in maintaining revenues and earnings in 2012, supported by a robust pipeline and effective cost management. The positive outlook and commitment to shareholder returns suggest a short-term positive impact on the stock price.

[1]